1DXCM Stock Overview

A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details

1DXCM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 35.1% below our estimate of its fair value

Earnings are forecast to grow 19% per year

Earnings have grown 18.1% per year over the past 5 years

Analysts in good agreement that stock price will rise by 39%

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

DexCom, Inc. Competitors

DiaSorin

BIT:DIA

€5.4b

EL.En

BIT:ELN

€691.9m

Terumo

TSE:4543

JP¥4.1t

Shenzhen Mindray Bio-Medical Electronics

SZSE:300760

CN¥261.0b

Price History & Performance

Summary of share price highs, lows and changes for DexCom
Historical stock prices
Current Share Price	US$61.93
52 Week High	US$0
52 Week Low	US$0
Beta	1.5
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0.57%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1DXCM	IT Medical Equipment	IT Market
7D	n/a	2.6%	4.9%
1Y	n/a	-0.2%	11.4%

Return vs Industry: Insufficient data to determine how 1DXCM performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1DXCM performed against the Italian Market.

Price Volatility

Is 1DXCM's price volatile compared to industry and market?
1DXCM volatility
1DXCM Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.7%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.6%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1DXCM's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1DXCM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	10,250	Kevin Sayer	www.dexcom.com/global

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.

DexCom, Inc. Fundamentals Summary

How do DexCom's earnings and revenue compare to its market cap?
1DXCM fundamental statistics
Market cap	€24.53b
Earnings (TTM)	€506.36m
Revenue (TTM)	€3.54b

48.5x

P/E Ratio

6.9x

P/S Ratio

Is 1DXCM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1DXCM income statement (TTM)
Revenue	US$4.03b
Cost of Revenue	US$1.59b
Gross Profit	US$2.44b
Other Expenses	US$1.86b
Earnings	US$576.20m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 01, 2025

Earnings per share (EPS)	1.47
Gross Margin	60.46%
Net Profit Margin	14.29%
Debt/Equity Ratio	116.1%

How did 1DXCM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/29 08:38
End of Day Share Price	2025/04/29 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DexCom, Inc. is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Francis Mainwaring	Atlantic Equities LLP
Anand Vankawala	Avondale Partners
Jeffrey Johnson	Baird